Valion Bio names Dean Zikria interim CEO, sets pay
The agreement sets a $23,333 monthly fee and entitles Zikria to 50,000 RSUs, with another 50,000 subject to a stockholder plan increase and Special Committee approval.
Rhea-AI Filing Summary
Valion Bio, Inc. (VBIO) appointed Board member Dean Zikria interim Chief Executive Officer effective September 22, 2026; he remains a director. Under a consulting agreement, he is entitled to a $23,333 monthly fee and 50,000 restricted stock units (RSUs). Another 50,000 RSUs are contingent on an increase to the equity plan by stockholders and approval by the Board’s Special Committee. A cash bonus may be awarded upon closing a reverse merger, merger, or acquisition, as determined by the Board or its Compensation Committee. The agreement is scheduled to terminate January 22, 2027, unless mutually extended for up to 12 months from its effective date.
Sheryle Bolton resigned from the Board effective September 17, 2026; the company stated her resignation did not result from a disagreement. Thomas Jensen became Board and Compensation Committee chair, and Jared Malbin became Audit and Risk Committee chair. While serving as interim CEO, Zikria was removed as an independent member of three Board committees. Lisa Wolf continues as President, Chief Operating Officer, and Chief Financial Officer, reporting to Zikria.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Monthly consulting fee: $23,333 per month
Initial RSUs: 50,000 RSUs
Additional RSUs: 50,000 RSUs
+2 more
5 metrics
Monthly consulting fee
$23,333 per month
Fee under Dean Zikria’s consulting agreement
Initial RSUs
50,000 RSUs
Entitlement under the equity incentive plan
Additional RSUs
50,000 RSUs
Contingent on a stockholder plan increase and Special Committee approval
Agreement termination date
January 22, 2027
Unless the parties mutually extend the agreement
Potential extension
Up to 12 months
Mutual extension from the agreement’s effective date
Key Terms
restricted stock units, independent contractor, Animal Rule, Fast Track, +2 more
6 terms
restricted stock units financial
"entitled to receive 50,000 restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
independent contractor technical
"Mr. Zikria is and will be an independent contractor"
Animal Rule regulatory
"evaluated in animal models under the FDA’s Animal Rule"
A regulatory pathway that allows safety and effectiveness of drugs or vaccines to be judged primarily from well-controlled animal studies when human trials would be unethical or impossible, such as for treatments against rare, lethal exposures. It matters to investors because approval via this route can speed a product to market for urgent or niche needs but carries extra scientific and regulatory risk—think of it as accepting a high-quality dress rehearsal instead of a live show, with requirements for strong animal models and often additional post-approval obligations.
Fast Track regulatory
"received Fast Track and Orphan Drug designations from the FDA"
A fast track designation is a regulatory label that speeds up the review and communication between a drug developer and regulators for treatments addressing serious illnesses or unmet medical needs. For investors, it matters because it can shorten development time and reduce regulatory delays—like getting a VIP lane at the airport—raising the chance of earlier market access and potential revenue, though it does not guarantee approval.
Orphan Drug designations regulatory
"received Fast Track and Orphan Drug designations from the FDA"
A regulatory status granted to medicines that treat rare diseases, giving developers special incentives and protections — for example, reduced fees, tax benefits, and a period of exclusive marketing once approved. Think of it as a government “boost” that lowers development costs and shields a product from direct competition for a time; investors watch for it because it can raise a drug’s commercial value and reduce the financial risk of bringing a treatment for a small patient group to market.
Toll-like Receptor 5 agonist technical
"Entolimod is a novel Toll-like Receptor 5 agonist"
A toll-like receptor 5 (TLR5) agonist is a drug or molecule that binds to and activates TLR5, a protein on certain immune cells that senses bacterial flagellin and triggers innate immune responses. Think of TLR5 as a doorbell on immune cells and an agonist as the button that rings it, prompting inflammation or immune activation; investors care because this mechanism is used in vaccines and cancer or infectious‑disease therapies and affects clinical effects, safety, and regulatory review.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What role will Dean Zikria hold at Valion Bio (VBIO)?
Valion appointed Dean Zikria interim Chief Executive Officer, effective September 22, 2026. He remains a Board member. The company said he will oversee strategic priorities including Entolimod’s clinical advancement and the pursuit of commercial and government partnerships.
What compensation does Valion Bio (VBIO) provide its interim CEO?
Zikria is entitled to a $23,333 monthly fee and 50,000 RSUs. Another 50,000 RSUs are contingent on an increase to the equity plan by stockholders and Special Committee approval. A cash bonus may be awarded upon closing a strategic transaction, as determined by the Board or Compensation Committee.
When does Dean Zikria’s Valion Bio (VBIO) consulting agreement end?
The agreement is scheduled to terminate on January 22, 2027, unless the parties mutually extend it for up to 12 months from its effective date.
Who leads Valion Bio’s (VBIO) Board and committees after the changes?
Thomas Jensen became Board and Compensation Committee chair, and Jared Malbin became Audit and Risk Committee chair. Sheryle Bolton resigned from the Board effective September 17, 2026. Zikria left three Board committees while serving as interim CEO.
What development programs does Valion Bio (VBIO) describe?
Valion identifies Entolimod as its lead candidate, being developed as a potential medical countermeasure for Acute Radiation Syndrome. It is also advancing Entolasta, a next-generation TLR5 agonist for potential broader applications, including oncology supportive care. Entolimod has received Fast Track and Orphan Drug designations from the FDA.
AI-generated analysis. How Rhea-AI works. Not financial advice.
